Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. more
Time Frame | AQST | Sector | S&P500 |
---|---|---|---|
1-Week Return | -11.37% | -1.8% | -0.77% |
1-Month Return | -24.65% | -3.48% | 0.71% |
3-Month Return | -22.83% | -7.2% | 8.81% |
6-Month Return | 35.94% | -1.54% | 12.32% |
1-Year Return | 93.91% | 8.39% | 30.57% |
3-Year Return | -23.75% | 6.07% | 29.21% |
5-Year Return | -50.39% | 44.07% | 91.95% |
10-Year Return | -76.2% | 106.3% | 196.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 52.61M | 45.85M | 50.83M | 47.68M | 50.58M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":87.15,"profit":true},{"date":"2021-12-31","value":96.62,"profit":true},{"date":"2022-12-31","value":90.63,"profit":true},{"date":"2023-12-31","value":96.15,"profit":true}] |
Cost of Revenue | 20.36M | 12.96M | 14.99M | 19.39M | 20.83M | [{"date":"2019-12-31","value":97.74,"profit":true},{"date":"2020-12-31","value":62.23,"profit":true},{"date":"2021-12-31","value":71.96,"profit":true},{"date":"2022-12-31","value":93.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 32.25M | 32.88M | 35.84M | 28.29M | 29.75M | [{"date":"2019-12-31","value":89.97,"profit":true},{"date":"2020-12-31","value":91.75,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.94,"profit":true},{"date":"2023-12-31","value":83.01,"profit":true}] |
Gross Margin | 61.30% | 71.72% | 70.51% | 59.34% | 58.82% | [{"date":"2019-12-31","value":85.46,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.31,"profit":true},{"date":"2022-12-31","value":82.74,"profit":true},{"date":"2023-12-31","value":82.01,"profit":true}] |
Operating Expenses | 84.92M | 75.78M | 70.52M | 70.36M | 44.85M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.24,"profit":true},{"date":"2021-12-31","value":83.05,"profit":true},{"date":"2022-12-31","value":82.86,"profit":true},{"date":"2023-12-31","value":52.82,"profit":true}] |
Operating Income | (52.67M) | (42.89M) | (34.68M) | (42.07M) | (15.10M) | [{"date":"2019-12-31","value":-5266800000,"profit":false},{"date":"2020-12-31","value":-4289300000,"profit":false},{"date":"2021-12-31","value":-3467900000,"profit":false},{"date":"2022-12-31","value":-4206600000,"profit":false},{"date":"2023-12-31","value":-1510200000,"profit":false}] |
Total Non-Operating Income/Expense | (22.26M) | (25.78M) | (57.90M) | (24.69M) | 16.34M | [{"date":"2019-12-31","value":-136.26,"profit":false},{"date":"2020-12-31","value":-157.81,"profit":false},{"date":"2021-12-31","value":-354.42,"profit":false},{"date":"2022-12-31","value":-151.13,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (66.25M) | (55.78M) | (70.54M) | (54.41M) | (7.63M) | [{"date":"2019-12-31","value":-6624600000,"profit":false},{"date":"2020-12-31","value":-5578300000,"profit":false},{"date":"2021-12-31","value":-7053900000,"profit":false},{"date":"2022-12-31","value":-5441000000,"profit":false},{"date":"2023-12-31","value":-762500000,"profit":false}] |
Income Taxes | 6.41M | 9.58M | 19.50M | 5.79M | 245.00K | [{"date":"2019-12-31","value":32.89,"profit":true},{"date":"2020-12-31","value":49.13,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":29.71,"profit":true},{"date":"2023-12-31","value":1.26,"profit":true}] |
Income After Taxes | (72.66M) | (65.36M) | (90.04M) | (60.20M) | (7.87M) | [{"date":"2019-12-31","value":-7265900000,"profit":false},{"date":"2020-12-31","value":-6536200000,"profit":false},{"date":"2021-12-31","value":-9003600000,"profit":false},{"date":"2022-12-31","value":-6020200000,"profit":false},{"date":"2023-12-31","value":-787000000,"profit":false}] |
Income From Continuous Operations | (66.25M) | (55.78M) | (70.54M) | (54.41M) | (7.87M) | [{"date":"2019-12-31","value":-6624600000,"profit":false},{"date":"2020-12-31","value":-5578300000,"profit":false},{"date":"2021-12-31","value":-7053900000,"profit":false},{"date":"2022-12-31","value":-5441000000,"profit":false},{"date":"2023-12-31","value":-787000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (72.66M) | (65.36M) | (90.04M) | (60.20M) | (7.87M) | [{"date":"2019-12-31","value":-7265900000,"profit":false},{"date":"2020-12-31","value":-6536200000,"profit":false},{"date":"2021-12-31","value":-9003600000,"profit":false},{"date":"2022-12-31","value":-6020200000,"profit":false},{"date":"2023-12-31","value":-787000000,"profit":false}] |
EPS (Diluted) | (2.43) | (1.65) | (1.49) | (1.14) | (0.36) | [{"date":"2019-12-31","value":-243,"profit":false},{"date":"2020-12-31","value":-165,"profit":false},{"date":"2021-12-31","value":-149,"profit":false},{"date":"2022-12-31","value":-114,"profit":false},{"date":"2023-12-31","value":-36,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
AQST | |
---|---|
Cash Ratio | 5.14 |
Current Ratio | 6.37 |
Quick Ratio | 5.91 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AQST | |
---|---|
ROA (LTM) | -15.57% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AQST | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.41 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.41 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AQST | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.91 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 5.33 |
EV/Ebitda | NM |
Aquestive Therapeutics Inc (AQST) share price today is $3.82
Yes, Indians can buy shares of Aquestive Therapeutics Inc (AQST) on Vested. To buy Aquestive Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AQST stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Aquestive Therapeutics Inc (AQST) via the Vested app. You can start investing in Aquestive Therapeutics Inc (AQST) with a minimum investment of $1.
You can invest in shares of Aquestive Therapeutics Inc (AQST) via Vested in three simple steps:
The 52-week high price of Aquestive Therapeutics Inc (AQST) is $6.23. The 52-week low price of Aquestive Therapeutics Inc (AQST) is $1.84.
The price-to-earnings (P/E) ratio of Aquestive Therapeutics Inc (AQST) is
The price-to-book (P/B) ratio of Aquestive Therapeutics Inc (AQST) is 0.00
The dividend yield of Aquestive Therapeutics Inc (AQST) is 0.00%
The market capitalization of Aquestive Therapeutics Inc (AQST) is $348.30M
The stock symbol (or ticker) of Aquestive Therapeutics Inc is AQST